© 2024 HSP News Service, L.L.C.
Jonathan D. Spicer, MD, PhD, of McGill University, discusses findings from the KEYNOTE-671 study of perioperative pembrolizumab for patients with resectable early-stage non–small cell lung cancer (NSCLC). Neoadjuvant pembrolizumab plus chemotherapy followed by resection and adjuvant pembrolizumab improved overall survival compared with neoadjuvant chemotherapy and resection alone in stage II, IIIA, or IIIB (N2) disease (Abstract LBA56).
A perioperative regimen of neoadjuvant nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab achieved a statistically significant and clinically meaningful improvement in event-free survival compared with neoadjuvant chemotherapy plus placebo followed by surgery and adjuvant...
The TROP-2–directed antibody-drug conjugate datopotamab deruxtecan may significantly improve progression-free survival in patients with metastatic non–small cell lung cancer (NSCLC), especially in patients with non–squamous cell tumors, according to new findings simultaneously published by Ahn et...
In a Dutch single-institution phase II trial (PEMMELA) reported in The Lancet Oncology, Douma et al found that the combination of pembrolizumab and lenvatinib showed activity as second- and third-line treatments of patients with pleural mesothelioma. Study Details A total of 38 evaluable patients...
Intensity-modulated radiation therapy (IMRT) reduced the risk of toxicity to the lungs and radiation exposure to the heart vs three-dimensional conformal radiotherapy (3D-CRT) for the treatment of locally advanced non–small cell lung cancer (NSCLC), according to a planned long-term prospective...
Early-phase trials demonstrate the potential for TROP-2–directed antibody-drug conjugates to enhance the response to immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC) without actionable genomic alterations, several investigators reported at the International...
The treatment of patients with epidermal growth factor receptor (EGFR)-mutated lung cancer that progresses on EGFR-targeted tyrosine kinase inhibitors has been challenging. In the phase II HERTHENA-Lung01 trial, the topoisomerase-1 HER3-targeting antibody-drug conjugate patritumab deruxtecan...
In a study reported in a research letter in JAMA Oncology, Jemal et al found that rates of lung cancer declined more in men vs women in the United States in recent years, such that incidence is now higher in women vs men aged ≤ 55 years. As stated by the investigators, “A previous study from the...
Tina Cascone, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses new phase III findings from the CheckMate 77T trial of patients with previously untreated resectable stage II–IIIB non–small cell lung cancer (NSCLC). The trial showed clinically meaningful improvement in event-free survival with neoadjuvant nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab vs chemotherapy or placebo (Abstract LBA1).
Compared with neoadjuvant chemotherapy alone, adding perioperative immunotherapy—given before and after surgery—significantly improved event-free survival in patients with resectable early-stage non–small cell lung cancer (NSCLC). Results from the phase III CheckMate 77T study were presented at the ...
The combination of the ATR inhibitor ceralasertib and the immune checkpoint inhibitor durvalumab has demonstrated notable survival rates and clinical benefits among patients who have advanced non–small cell lung cancer (NSCLC) with RAS mutations, according to data presented at the International...
In a phase II trial reported in JAMA Oncology, Takahashi et al found that the addition of the ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor berzosertib to topotecan did not improve progression-free survival in patients with relapsed small cell lung cancer (SCLC). However, an overall ...
On October 16, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent pembrolizumab as postsurgical adjuvant treatment, for resectable (tumors ≥ 4 cm or node-positive)...
Lung cancer is a significant global health issue, remaining the leading cause of cancer-related deaths with 2.1 million new cases and 1.8 million deaths. Complete surgical resection is the treatment of choice for operable early-stage non–small cell lung cancer (NSCLC) and resectable stage IIIA...
On October 11, the U.S. Food and Drug Administration (FDA) approved the BRAF inhibitor encorafenib (Braftovi) with the MEK inhibitor binimetinib (Mektovi) for adult patients with metastatic non–small cell lung cancer (NSCLC) and a BRAF V600E mutation, as detected by an FDA-approved test. The FDA...
In the phase III CANOPY-A trial reported in Journal of Clinical Oncology, Edward B. Garon, MD, and colleagues found that adjuvant therapy with the interleukin (IL)-1β pathway inhibitor canakinumab did not significantly improve disease-free survival vs placebo in patients with completely resected...
Justin F. Gainor, MD, Director of the Center for Thoracic Cancers Program at Massachusetts General Hospital, Boston, was invited to discuss IMpower151 and ILLUMINATE at the 2023 World Conference on Lung Cancer. IMpower151 vs IMpower150 Dr. Gainor examined why IMpower151 was negative for both...
In advanced non–small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR), the role of immune checkpoint inhibitors following disease progression with tyrosine kinase inhibitors has been unclear. Several studies reported at the International Association for the Study ...
Roy S. Herbst, MD, PhD, cautioned that although FLAURA2 is a positive result, most patients will still develop drug resistance. “The result is really good and clearly positive, but if you look at the survival curves, there is still early overlap in a way that makes it unlikely this combination will ...
First-line treatment with osimertinib plus platinum-based chemotherapy achieved a statistically significant and clinically meaningful progression-free survival improvement compared with osimertinib alone in patients with advanced epidermal growth factor receptor (EGFR)-mutated non–small cell lung...
In a phase II study (iSABR) reported in JAMA Oncology, Gensheimer et al found that individualized stereotactic ablative radiotherapy (SABR) for up to four lung cancer tumors was associated with a high degree of local control and the ability to minimize radiation doses. Study Details Two hundred and ...
At the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer, the benefit of two KRAS G12C inhibitors in advanced non–small cell lung cancer (NSCLC) was upheld by the 2-year follow-up analysis of adagrasib in the KRYSTAL-11 and the early-phase CodeBreaK 101...
Gilberto de Lima Lopes, Jr, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, comments on four presentations from the 2023 World Conference on Lung Cancer for which he served as discussant: the global landscape of three types of lung cancer (squamous cell, adenocarcinoma, and small cell); findings from the Australian Registry and Biobank of Thoracic Cancers; the Registry of Genetic Alterations of Taiwan by comprehensive next-generation sequencing; and treatment decisions in octogenarians with non-small cell lung cancer.
Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses results of the VISION trial, the largest on-treatment liquid biopsy biomarker data set of a MET inhibitor in patients with MET exon 14 non–small cell lung cancer (NSCLC). Tepotinib showed durable efficacy in this population.
Ilias Houda, MD, PhD Candidate, of Amsterdam University Medical Centers, discusses the differing opinions of thoracic surgeons when it comes to resection for stage III non–small cell lung cancer (NSCLC). The international EORTC survey showed there is no consensus, although respondents were more likely to consider some stage III TNM combinations to be potentially resectable.
Seshiru Nakazawa, MD, PhD, of Dana-Farber Cancer Institute, discusses activating the MET tyrosine kinase domain mutation, which has been identified as the sole oncogenic mutation in a small but significant subset of patients with non–small cell lung cancer (NSCLC). According to Dr. Nakazawa’s findings, this mutation is potentially targetable with currently available MET tyrosine kinase inhibitors.
Shirish M. Gadgeel, MD, of the Henry Ford Cancer Institute, discusses a 5-year follow-up study of patients with metastatic non–small cell lung cancer (NSCLC) who were treated with pembrolizumab plus chemotherapy. According to Dr. Gadgeel, the findings continue to support the use of pembrolizumab plus chemotherapy as a standard-of-care first-line treatment, including in tumors with a PD-L1 tumor proportion scores of less than 1%.
Recent developments in surgery and therapeutics are changing the perioperative approach to non–small cell lung cancer (NSCLC). These advances were discussed at the 2023 Debates and Didactics in Hematology and Oncology conference, sponsored by Emory University, by Jennifer W. Carlisle, MD, Assistant ...
Yasir Y. Elamin, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from the BRIGHTSTAR study, in which brigatinib with local consolidative therapy was found to be safe in patients with ALK-rearranged advanced non–small cell lung cancer. This regimen yielded promising outcomes when compared with historical outcomes with brigatinib alone (Abstract OA22.04).
Chee K. Lee, PhD, MBBS, of the University of Sydney, discusses findings of the ILLUMINATE study, which showed durvalumab and tremelimumab with chemotherapy yielded antitumor activity in patients with non–small cell lung cancer (NSCLC) whose tumors progressed after receiving EGFR inhibitors. This result was especially marked in those with EGFR T790M–negative tumors (Abstract OA09.04).
David H. Harpole, Jr, MD, of Duke University Medical Center, discusses further exploratory analyses of patients with EGFR-mutated resectable non–small cell lung cancer (NSCLC) enrolled in the phase III AEGEAN study. In this trial, perioperative durvalumab plus neoadjuvant chemotherapy, vs neoadjuvant chemotherapy alone, significantly improved event-free survival and pathologic complete response (Abstract OA12.06).
Ticiana A. Leal, MD, of Winship Cancer Institute at Emory University, discusses phase III findings from the LUNAR study of tumor treating fields (electric fields that disrupt cellular processes and lead to cell death) combined with the standard of care in patients with metastatic non–small cell lung cancer (NSCLC) after relapse on platinum treatment. The survival benefit of this regimen was especially profound in patients with tumor PD-L1 expression who received an immune checkpoint inhibitor as the standard of care, according to Dr. Leal (Abstract OA22.05).
Neoadjuvant immunotherapy may be effective prior to surgery in multiple types of cancers, according to a recent study published by Topalian et al in Cancer Cell. Background Neoadjuvant immune checkpoint blockades have been a rapidly growing area of research and are currently being tested across...
Tom E. Stinchcombe, MD, of Duke Cancer Institute, discusses an analysis of the rate of second primary lung cancer from the CALGB (Alliance) 140503 trial of lobar vs sublobar resection for T1a N0 non–small cell lung cancer (NSCLC). The data have implications for surveillance and screening strategies for patients with resected stage I disease (Abstract OA12.03).
In an Australian phase III trial (TARGET-TP) reported in JAMA Oncology, Alexander et al found that ambulatory thromboprophylaxis reduced the risk of thromboembolic events in patients starting systemic therapy for lung or gastrointestinal cancer who were at elevated risk of thrombosis. Study ...
As reported in the Journal of Clinical Oncology by Goto et al, primary results of the phase II DESTINY-Lung02 trial have shown activity of fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (NSCLC) previously treated with platinum-containing...
In patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR mutations, the role of immune checkpoint inhibitors following disease progression with tyrosine kinase inhibitors has been unclear. Several studies reported at the International Association for the Study of Lung Cancer 2023 ...
The biomarker-driven Lung Cancer Master Protocol (Lung-MAP) may have enrolled a higher percentage of patients who are older, are from rural or socioeconomically deprived areas, and have Medicaid or no insurance compared with conventional, standalone clinical trials in advanced non–small cell lung...
In a 5-year analysis of the Japanese phase III JIPANG trial reported in the Journal of Clinical Oncology, Kenmotsu et al found no significant differences in overall or recurrence-free survival with adjuvant pemetrexed/cisplatin vs vinorelbine/cisplatin in patients with stage II–IIIA nonsquamous...
In the phase II HERTHENA-Lung01 trial reported in the Journal of Clinical Oncology, Helena Yu, MD, and colleagues found that patritumab deruxtecan (HER3-DXd), a new anti-HER3 antibody-drug conjugate, showed activity in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC)...
The anti–PD-L1 monoclonal antibody durvalumab in combination with other immuno-oncology agents may outperform treatment with durvalumab alone in the neoadjuvant setting for patients with early-stage non–small cell lung cancer (NSCLC), according to a recent study published by Cascone et al in Cancer ...
Investigators have discovered that women with certain reproductive factors may have an elevated risk of developing lung cancer, according to recent findings presented by Zhang et al at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (Abstract...
The Lung Cancer Action Network (LungCAN) advocacy program may have helped increase funding for the U.S. Department of Defense Congressionally Directed Medical Research Program/Lung Cancer Research Program (LCRP) by 25%, according to recent findings presented by Donaldson et al at the International...
Researchers have validated the accuracy of the International Association for the Study of Lung Cancer’s (IASLC) 2009 pleural mesothelioma database, with these findings presented by Wolf et al at the IASLC 2023 World Conference on Lung Cancer (Abstract MA17.04). Background Pleural mesothelioma often ...
Intensity-modulated radiation therapy may be the preferred treatment option for patients with locally advanced non–small cell lung cancer (NSCLC), according to findings presented by Chun et al at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer ...
The combination of benmelstobart, anlotinib, and chemotherapy may be effective at improving median progression-free survival and overall survival in patients with extensive-stage small cell lung cancer compared with placebo and chemotherapy, according to findings presented by Cheng et al at the...
The stigma that patients face when diagnosed with lung cancer may be associated with poorer psychosocial outcomes, including distress and isolation, delayed help-seeking, and concerns about the quality of care, according to findings presented by Harrison et al at the International Association for...
The oral KRAS G12C inhibitor adagrasib may offer durable clinical activity, with a median overall survival of 14.1 months and a 2-year survival rate of about 33%, in patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC), according to findings presented by Gadgeel et al at the...
Researchers have discovered that therapy with first-line nivolumab in combination with ipilimumab may improve the 6-year survival and quality of life of patients with metastatic non–small cell lung cancer (NSCLC) compared with standard chemotherapy, according to findings presented by Peters et al...
The addition of perioperative durvalumab to neoadjuvant chemotherapy may be associated with a tolerable surgical safety profile and may not adversely impact surgery in patients with resectable non–small cell lung cancer (NSCLC), according to new findings presented by Mitsudomi et al at the...